Avaxim 80 U Pediatric Prevention of infection induced by HAV in childn 12 mth-15 yr. Avaxim Adult Prevention of infection caused by HAV in adults >16 yr.
Avaxim 80 U Pediatric 0.5 mL IM inj into the deltoid region followed by booster dose preferably 6-36 mth after the primary vaccination & may be administered up to 7 yr after primary vaccination. Avaxim Adult 0.5 mL IM into the deltoid region followed by booster dose preferably 6-12 mth later for adult >16 yr & can be administered up to 36 mth after the 1st vaccination. Can also be administered as a booster dose of hepatitis A vaccine after receiving combined typhoid fever & hepatitis A vaccine 6-36 mth earlier.
Hypersensitivity to the vaccine, neomycin & previous inj of vaccine. Postpone vaccination in patients suffering from fever, acute illness, chronic progressive disease.
Anaphylactic reaction. Not to be inj intravascularly, intradermally or into the buttocks. Not a protection against infection caused by HBV, HCV, hepatitis E virus or other known liver pathogens. Immunodeficient patients or on immunosuppressive treatment. Syncope; phenylketonuria. Not to be mixed w/ other vaccines. Liver disease. Not to be used during pregnancy. Not recommended during lactation.
Avaxim 80 U Pediatric Concomitant immunosuppressive treatment may diminish immunological response. Simultaneous administration of Ig may lower Ab titers. Not to be mixed w/ other vaccines in the same syringe.
Sign Out
